The initial public offering (IPO) market posted a busy week last week after a slow start to the month with 13 traditional IPOs raising over $3.58 billion.

In the biggest deal of the week, Stevanato Group S.p.A. (STVN  ) priced its downsized offering at the low end to raise $672 million. The Italian drug container supplier produces glass vials, syringes, and other containers for over 700 companies within the pharmaceutical and life sciences industry. The stock ended the week down 6%.

In the week's best performance, Sight Sciences, Inc. (SGHT  ) finished the week up 36% after pricing its upsized offering at the high end to raise $240 million. The company develops and sell medical and surgical devices for eye diseases.

Here's the rest of the week's debuts in order of offering amount:

Phillips Edison & Company, Inc. (PECO  ) priced its offering at the low end to raise $476 million. The REIT owns equity interests in 300 shopping centers across the United States, focusing on locations owned by grocers like Kroger (KR  ) and Publix. The stock ended the week relatively flat.

Membership Collective Group, Inc. (MCG  ) priced its shares at the low end to raise $420 million. The luxury social club operator boasts a large and loyal member base and is known for its member-only hotel brand Soho Hotel. The stock finished down 11%.

Blend Labs, Inc. (BLND  ) priced its shares at the high end to raise $360 million. The company provides a software platform to financial services companies that offer mortgages and consumer loans. The stock finished the week up 16%.

F45 Training Holdings, Inc. (FXLV  ) priced its shares at its midpoint to raise $325 million. The Mark Wahlberg-backed fitness franchise offers 45-minute workouts across a global network of studios. The stock ended the week up 1%.

Bridge Investment Group Holdings, Inc. (BRDG  ) priced its shares at the midpoint to raise $300 million. The real estate investment manager specializes in equity and debt across multiple sectors. The stock ended the week down 2%.

Erasca, Inc. (ERAS  ) priced its upsized offering at the high end to raise $300 million. The oncology-focused biotech is developing therapies for RAS/MAPK pathway-driven cancers, with its lead candidate currently in Phase 2 trials for solid tumors. The stock finished up 9%.

Rapid Micro Biosystems, Inc. (RPID  ) priced its upsized offering at the high end to raise $158 million. The company provides an automated microbial testing device and platfrom for use within the pharmaceutical manufacturing industry. The stock ended the week up 21%.

Imago BioSciences, Inc. (IMGO  ) priced its upsized offering at the high end to raise $134 million. The biotech is developing small molecule therapies for the treatment of bone marrow diseases and cancer, with its lead candidate currently in Phase 2 trials for essential thrombocythemia. The stock finished up 2%.

TScan Therapeutics, Inc. (TCRX  ) priced its shares at the low end to raise $100 million. The cancer-focused biotech is genetically engineering T cell therapies for the treatment of cancer, with the company planning to submit Investigative New Drug (IND) forms for its lead two liquid tumor candidates by the end of this year and INDs for at least three of its four solid tumor candidates in the second half of 2022. The stock ended the week down 30%.

Sera Prognostics, Inc. (SERA  ) priced its shares at the midpoint to raise $75 million. The pregnancy diagnostic company uses its proteomics and bioinformatics platform to develop biomarker tests designed to improve pregnancy outcomes. The stock finished down 31%.

Regencell Bioscience Holdings Ltd. (RGC  ) priced its shares at the midpoint of its range to raise $22 million. The Chinese drug company is developing traditional Chinese medicines (TCM) for the treatment for neurocognitive disorders, with three TCM formula candidates in development. The stock finished the week up 11%.